FAS-670A/G polymorphism analysis did not reveal any association with BCG therapy outcome.
INTRODUCTION
The Fas/Fas ligand (FasL) system is one of the major pathways of apoptosis and an important regulator of cell proliferation and immune system regulation. During carcinogenesis, tumor cells may alter this mechanisms to subvert the immune system and suppress the antitumor immune response [1] .
Fas/FasL further controls T cell apoptosis after immune reaction by the process of activation-induced cell death (AICD) [2] . This mechanism involves the overexpression of both Fas and FasL upon activation by antigen or other stimuli, subsequently pro oti g ell suicide or fratricide [3] . Decreased Fas and elevated FasL expression has been found in many types of cancer including bladder cancer [4] . It has been shown that tumor cells may counterattack Fas-sensitive tumor-infiltrating lymphocytes (TILs) using heightened expression of FasL. This mechanism is thought to lead to tumor cell immune escape, thus contributing to cancer formation and progression [5] .
Functional polymorphisms in the promoter region of FAS and FASL genes have been identified and alter the transcriptional activity of these genes, which may have implications in the Fas/FasL pathways [6, 7] . Moreover, they have been associated with a higher risk in various cancer models [8, 9] . In bladder cancer, FASL-844 CC genotype was associated with a significantly increased risk of bladder cancer [10] . However, the role of Fas/FasL and its functional polymorphisms have not been addressed in the context of bladder cancer treatment.
At the moment, the most effective treatment for high risk non-muscle invasive bladder cancer (NMIBC) consists of an immunotherapy with bacillus Calmette-Guérin (BCG) [11] .
Generally it is performed as adjuvant to transurethral resection of bladder tumor (TURBT) in intermediate and high risk patients [11] . However, several studies demonstrated that 30% of the patients fail to respond to this therapeutic and in some cases the tumor may become more aggressive [12] . Thus, early identification of patients better served by alternative and/or more aggressive approaches such as cystectomy is a critical aspect in the management of high-risk NMIBC [13, 14] . However, at the moment there are no established biomarkers to determine the outcome of BCG immunotherapy. Recently, several authors suggest that immunological predictive markers may yield promising clinical value in the context of predicting BCG immunotherapy outcome [14] [15] [16] .
One of the main pathways of BCG anti-tumoral response is mediated by BCG and lymphokine-activated killer cells (BAK and LAK) [17] . Although it has been demonstrated that Fas/FasL pathway is not directly involved in BCG anti-tumoral effect [17, 18] , BCG effector cells are sensitive to FasL-dependent AICD regulation [2] and possibly to FasL counterattack by tumor cells. Hypothesizing that a deregulation of Fas/FasL pathway may lead to immune escape and influence the efficacy of BCG immunotherapy, in this study we aimed to evaluate the role of FAS and FASL polymorphisms in the context of BCG therapy response. To the best of our knowledge, this is the first study addressing this subject and may provide important insights about the role of these molecules as predictive markers of BCG treatment outcome.
MATERIAL AND METHODS

Population
In this retrospective case-control study, all intermediate and high-risk NMIBC patients who underwent transurethral resection followed by BCG therapy between 1998 and 2006 at the Portuguese Institute of Oncology -Porto were eligible for this study. From a total of 193 patients, 14 had already died. The remaining 179 were invited to participate in the study, 70% of which accepted [19] . Patients blood samples were collected during 2006 and 2008 on patie t's follo -up consultation. All patients received intravesical instillation of BCG for 6 consecutive weeks starting 2-3 weeks after surgery, i.e., induction scheme (iBCG) and 56% underwent further instillations every 3 months for two years, i.e., maintenance scheme (mBCG). The iBCG group includes patients treated before the European Association of Urology guidelines recommending the mBCG scheme and patients showing significant intolerance to long BCG treatment. The mean diagnostic age of the patients was 61,54±10,63 (min:36; max:97) years, with a male:female sex ratio of 105:20. The patients were followed by cystoscopy and urinary cytology every 3 months for the first year, every 6 month for the second year and every 12 months thereafter. The median follow-up time was 60 months (from 6 till 135 months). Tumor recurrence was defined as a newly found bladder tumor after the treatment, with at least one tumor-free cystoscopy between. The end point of the study was recurrence-free survival (RFS), defined as the period between the beginning of BCG treatment until the date of the most recent cystoscopy or recurrence date. Non-responders, as opposed to responders, were defined as patients submitted to BCG treatment that showed tumor recurrence. All clinicopathological information was obtained fro patie ts' li i al re ords.
Informed and written consent from each patient was obtained. The institutional ethics committee approved the study.
DNA extraction and genotyping
Peripheral blood samples were collected following standard venipuncture technique in EDTA-containing tubes, and the DNA was extracted from the white blood cell fraction using a salting out protocol [20] and storage at -20ºC.
The FAS and FASL genetic polymorphisms were genotyped using RFLP-PCR technique.
The primers and enzymes used in FAS-670A/G and FASL-844T/C polymorphisms genotyping were the described by other authors [6, 7] . The PCR-RFLP conditions were the same as used by previously [20] . Genotyping data was read blind to the study endpoint. For quality control, 10% of the samples were randomly selected to a second PCR-RFLP analysis and 100% of concordance was observed.
RNA extraction and FASL mRNA expression analysis
A total of 34 tumor samples were randomly selected from the initial population according to the patient genotype for FASL-844T/C polymorphism (17 TT/TC and 17 CC). RNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissue samples using "Absolutely 
Assessment of FasL expression by immunohistochemistry
The same 34 FFPE tissue sections were screened for FasL by immunohistochemistry with the streptavidin/biotin peroxidase method using anti-FasL mouse monoclonal antibody clone 5D1 (Leica Biosystems, Wetzlar, Germany). Tissues 
Statistical analysis
Statistical data analysis was carried out using the computer software Statistical Package for Social Sciences-SPSS for Windows (version 15.0). Chi-square analysis was used to compare categorical variables. The odds ratio (OR) and its 95% confidence interval (CI) were calculated as a measurement of the association between genotypes and the risk of recurrence.
Kaplan-Meier survival curves were used to evaluate correlation between genotypes and RFS and were compared by log-rank statistical test. Further, multiple Cox regression analysis was used to assess the effect of individual polymorphisms on the time to recurrence in BCG-treated patients and to adjust for potential confounders. Non parametric Mann-Whitney test was used to compare the differences in the mRNA expression between the study groups.
RESULTS
FAS and FASL polymorphisms as predictors of BCG immunotherapy outcome
Regarding the evaluation of FAS-670A/G and FASL-844T/C polymorphisms, Table 1 presents genotype frequencies and the risk of recurrence after BCG treatment. The relation between clinicopathological characteristics and response to BCG treatment (i.e., responders vs. non-responders) is presented in Table 2 . It was observed that treatment scheme is associated with recurrence after treatment (35.1% vs. 58.3%, p=0.011).
Our previous report, with the same sample dataset, showed that iBCG treated patients or patients with multiple tumors have a shorter RFS [19] . In the present study we performed 
FASL mRNA expression and its relation with FASL-844T/C and treatment response
Of the 125 patients, 34 tumor tissues were available for evaluation of FASL mRNA expression levels. As shown in Fig. 2 Kaplan-Meier analysis (Fig. 3) 
DISCUSSION
The management of high-risk NMIBC relies mostly on an adjuvant immunotherapy consisting on intravesical instillations with BCG, performed after transurothelial resection of the tumor [11] . BCG promotes a strong local immune response that results in tumor elimination [13, 21, 22 ]. In our most recent systematic review on this subject we point out several markers such as CD68, ezrin, HSP90, CD83, IL2 urinary levels related with BCG response [14] . Several functional polymorphisms in genes such as NRAMP1, hGPX1, XPA, ERCC2 and 6 as well as in genes involved in inflammatory pathways (IL8, TNFA, IL6, TGFB1, COX2, IFNG) [14] .
All these genetic markers have been identified based on a candidate gene approach using well established polymorphisms. Still, at the moment there are no reliable biomarkers to determine the outcome of this therapeutics, thereby permitting the early identification of patients better served by alternative therapeutics or cystectomy [14, 16] . It has been long thought that such biomarkers may be encountered among molecules/cells involved in the mediation of immune responses at the tumor site [14] [15] [16] . Among these putative immune-related biomarkers is the Given the putative involvement Fas/FasL pathway on the immune response, one may hypothesize that functional polymorphisms affecting expression levels of this molecules may deregulate this pathway contributing to the failure of BCG therapeutics [15] . Therefore it may be used as a predictive biomarker of BCG immunotherapy outcome.
Since the FASL-844T/C polymorphism was never evaluated in the context of BCG Herein we opted to extract RNA from FFPE tissues. Although mRNA extracted from FFPE is partial degraded, is possible to use this in real time PCR to obtain accurate and specific gene expression using amplicons under 100bp [25] . Based on these observations we choose amplicons lower than 100bp. We also observed that GADPH expression was stable among our samples and that the mean Ct was around 30. According to several authors this is an indicator of mRNA quality and amplification efficiency [25, 26] . Based in these concepts we can say that our RNA samples were suitable for expression analysis.
Regarding FAS-670A/G analysis, we could confirm that this polymorphism is not associated with BCG treatment outcome in the Portuguese population, as described for the Table 3 
